Semaglutide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Semaglutide" in English language version.

refsWebsite

Global rank English rank

60web.archive.org

1^st place

41nih.gov

4^th place

28doi.org

2^nd place

13fda.gov

447^th place

338^th place

11clinicaltrials.gov

5,225^th place

4,062^nd place

10semanticscholar.org

11^th place

8^th place

8europa.eu

68^th place

117^th place

6nytimes.com

7^th place

4worldcat.org

5^th place

4hres.ca

low place

3tga.gov.au

3,984^th place

2,622^nd place

3medicines.org.uk

3,823^rd place

2,387^th place

3washingtonpost.com

34^th place

27^th place

3reuters.com

49^th place

47^th place

3cnn.com

28^th place

26^th place

2funnelback.com

low place

2clincalc.com

3,912^th place

2,496^th place

2globenewswire.com

2,614^th place

1,549^th place

2npr.org

92^nd place

72^nd place

1canada.ca

1,712^th place

1,063^rd place

1qut.edu.au

8,570^th place

5,097^th place

1statnews.com

8,771^st place

5,253^rd place

1handle.net

102^nd place

76^th place

1wired.com

193^rd place

152^nd place

1spiegel.de

66^th place

350^th place

1jpma.org.pk

low place

1drugs.com

399^th place

333^rd place

1novonordisk.com

low place

1prnewswire.com

406^th place

258^th place

1kff.org

low place

8,628^th place

1drugpatentwatch.com

low place

1pharmaceutical-technology.com

low place

1labiotech.eu

low place

1theglobeandmail.com

293^rd place

203^rd place

1cnbc.com

220^th place

155^th place

1medicaleconomics.com

low place

1advisory.com

low place

1nice.org.uk

3,258^th place

2,666^th place

1yle.fi

380^th place

933^rd place

1pbs.gov.au

low place

1abc.net.au

139^th place

108^th place

1gov.uk

432^nd place

278^th place

1theguardian.com

12^th place

11^th place

1goodrx.com

low place

1people.com

31^st place

25^th place

1bbc.com

20^th place

30^th place

1medrxiv.org

low place

1lww.com

2,769^th place

3,314^th place

1medium.com

551^st place

406^th place

abc.net.au

Verrender I (19 December 2023). "How Ozempic could affect the health of the global economy in more ways than one". ABC News. Archived from the original on 18 December 2023. Retrieved 18 December 2023.

advisory.com

"Charted: The cost of weight-loss drugs in the US vs. Other countries". Archived from the original on 20 January 2024. Retrieved 8 April 2024.

bbc.com

"Weight-loss jabs investigated for suicide risk". BBC News. 10 July 2023. Archived from the original on 10 July 2023. Retrieved 10 July 2023.

canada.ca

"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Archived from the original on 17 April 2024. Retrieved 17 April 2024.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Semaglutide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

clinicaltrials.gov

"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide". ClinicalTrials.gov. August 2019. Retrieved 26 December 2024.
"Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)". ClinicalTrials.gov. October 2019. Archived from the original on 31 July 2018. Retrieved 3 March 2023.
"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (SUSTAIN 1)". ClinicalTrials.gov. 28 May 2019. Retrieved 26 December 2024.
"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes (SUSTAIN 5)". ClinicalTrials.gov. 28 May 2019. Retrieved 26 December 2024.
"ClinicalTrials.gov". ClinicalTrials.gov. 28 May 2019. Retrieved 26 December 2024.
"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN 2)". ClinicalTrials.gov. 28 May 2019. Retrieved 26 December 2024.
"Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN 4)". ClinicalTrials.gov. 28 May 2019. Retrieved 26 December 2024.
"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (SUSTAIN)". ClinicalTrials.gov. 21 June 2018. Retrieved 26 December 2024.
"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)". ClinicalTrials.gov. 21 December 2017. Retrieved 26 December 2024.
"Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6)". ClinicalTrials.gov. 20 June 2019. Retrieved 26 December 2024.
"STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)". ClinicalTrials.gov. 18 November 2021. Retrieved 26 December 2024.

cnbc.com

"Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses". 9 July 2025.

cnn.com

Dillinger K (29 March 2023). "WHO advisers to consider whether obesity medication should be added to Essential Medicines List". CNN. Archived from the original on 30 March 2023. Retrieved 30 March 2023.
He L (7 June 2023). "Ozempic is taking China by storm. Drugmakers are scrambling to boost supplies". CNN Business. Archived from the original on 15 December 2023. Retrieved 1 December 2023.

edition.cnn.com

Goodman B (20 May 2024). "People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies confirm". CNN. Retrieved 29 September 2024.

doi.org

Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.
Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982.
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.
Goldenberg RM, Steen O (March 2019). "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes". Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966.
Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (November 2023). "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss". JAMA. 330 (18): 1795–1797. doi:10.1001/jama.2023.19574. PMC 10557026. PMID 37796527.
Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA (April 2020). "Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials". Diabetes, Obesity & Metabolism. 22 (4): 699–704. doi:10.1111/dom.13924. PMID 31750601.
Sande CM, Tondi Resta I, Livolsi VA (March 2023). "The Thyroid Pathologist Meets Therapeutic Pharmacology". Endocrine Pathology. 34 (1): 48–56. doi:10.1007/s12022-023-09749-1. PMC 9890439. PMID 36723855.
Shor R, Mihalache A, Noori A, Shor R, Kohly RP, Popovic MM, et al. (5 June 2025). "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration". JAMA Ophthalmology. doi:10.1001/jamaophthalmol.2025.1455. ISSN 2168-6165. PMC 12142475. PMID 40471562.
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. (April 2010). "Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation". Endocrinology. 151 (4): 1473–1486. doi:10.1210/en.2009-1272. PMID 20203154. S2CID 20934882.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. (November 2016). "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 375 (19): 1834–1844. doi:10.1056/NEJMoa1607141. hdl:11268/7179. PMID 27633186.
Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D (2003). "Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis". The Journal of Biological Chemistry. 278 (1): 471–478. doi:10.1074/jbc.M209423200. PMID 12409292.
Dhillon S (February 2018). "Semaglutide: First Global Approval". Drugs. 78 (2): 275–284. doi:10.1007/s40265-018-0871-0. PMID 29363040. S2CID 46851453.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. (September 2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (September 2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide". Journal of Medicinal Chemistry. 58 (18): 7370–80. doi:10.1021/acs.jmedchem.5b00726. PMID 26308095. S2CID 20228358.
Gotfredsen CF, Mølck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, et al. (July 2014). "The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates". Diabetes. 63 (7): 2486–97. doi:10.2337/db13-1087. PMID 24608440. S2CID 35102048.
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A (May 2015). "Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel". Journal of Clinical Pharmacology. 55 (5): 497–504. doi:10.1002/jcph.443. PMC 4418331. PMID 25475122.
Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". The New England Journal of Medicine. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID 33567185. S2CID 231883214.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. (October 2022). "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial". Nature Medicine. 28 (10): 2083–2091. doi:10.1038/s41591-022-02026-4. PMC 9556320. PMID 36216945.
Müller TD, Blüher M, Tschöp MH, DiMarchi RD (March 2022). "Anti-obesity drug discovery: advances and challenges". Nature Reviews. Drug Discovery. 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. PMC 8609996. PMID 34815532.
Claxton G, Rae M, Damico A, Winger A, Wager E (November 2024). "Health Benefits In 2024: Higher Premiums Persist, Employer Strategies For GLP-1 Coverage And Family-Building Benefits". Health Affairs. 43 (11): 1491–1501. doi:10.1377/hlthaff.2024.01006. PMID 39381848.
Tichy EM, Hoffman JM, Tadrous M, Rim MH, Cuellar S, Clark JS, et al. (July 2024). "National trends in prescription drug expenditures and projections for 2024". American Journal of Health-System Pharmacy. 81 (14): 583–598. doi:10.1093/ajhp/zxae105. PMID 38656319.
Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M (June 2022). "Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis". Diabetes & Metabolic Syndrome. 16 (6): 102539. doi:10.1016/j.dsx.2022.102539. PMID 35709586. S2CID 249584781.
Nagendra L, Bg H, Sharma M, Dutta D (July 2023). "Semaglutide and cancer: A systematic review and meta-analysis.". Diabetes Metab Syndr. 17 (9): 102834. doi:10.1016/j.dsx.2023.102834. PMID 37531876. S2CID 260261877.
Wilding JP, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. (August 2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension". Diabetes, Obesity & Metabolism. 24 (8): 1553–1564. doi:10.1111/dom.14725. PMC 9542252. PMID 35441470.
Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (April 2024). "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials". Expert Opinion on Pharmacotherapy. 25 (5): 611–619. doi:10.1080/14656566.2024.2343092. PMID 38629387.
Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, et al. (April 2025). "A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies". Journal of Drugs in Dermatology. 24 (4): 413–415. doi:10.36849/JDD.8605. PMID 40196945.

drugpatentwatch.com

"OZEMPIC Drug Patent Profile". Drug Patent Watch. Archived from the original on 23 March 2024. Retrieved 23 March 2024.

drugs.com

"Development Status and FDA Approval Process for semaglutide". Drugs.com. 2017. Archived from the original on 24 October 2017. Retrieved 24 October 2017.

europa.eu

ema.europa.eu

"Ozempic EPAR". European Medicines Agency (EMA). 8 February 2018. Archived from the original on 25 October 2020. Retrieved 26 September 2020.
"Rybelsus EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 14 August 2020. Retrieved 26 September 2020.
"Wegovy EPAR". European Medicines Agency. 6 January 2022. Archived from the original on 2 July 2022. Retrieved 11 March 2022.
"Wegovy: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 13 November 2021. Retrieved 13 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens". European Medicines Agency (Press release). 18 October 2023. Archived from the original on 4 January 2024. Retrieved 6 January 2024.

ec.europa.eu

"Ozempic PI". Union Register of medicinal products. 12 February 2018. Retrieved 26 December 2024.
"Rybelsus PI". Union Register of medicinal products. 7 April 2020. Retrieved 26 December 2024.
"Wegovy Product information". Union Register of medicinal products. Archived from the original on 30 October 2022. Retrieved 3 March 2023.

fda.gov

"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014". US Food and Drug Administration (FDA) (Press release). 4 June 2021. Archived from the original on 4 June 2021. Retrieved 5 June 2021.
"FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight". US Food and Drug Administration (FDA) (Press release). 8 March 2024. Archived from the original on 12 March 2024. Retrieved 12 March 2024. This article incorporates text from this source, which is in the public domain.
"Ozempic Drug Trial Snapshot". US Food and Drug Administration (FDA). 5 December 2017. Archived from the original on 31 December 2023. Retrieved 31 December 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves first oral GLP-1 treatment for type 2 diabetes" (Press release). US Food and Drug Administration (FDA). 20 September 2019. Archived from the original on 23 September 2019. Retrieved 20 September 2019.
"FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain". US Food and Drug Administration (FDA). 21 December 2023. Archived from the original on 22 December 2023. Retrieved 22 December 2023.
"Compounding when Drugs are on FDA's Drug Shortages List". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 28 September 2024. Retrieved 3 January 2025. This article incorporates text from this source, which is in the public domain.
"Compounding and the FDA: Q & A". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 3 January 2025. This article incorporates text from this source, which is in the public domain.
"FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 3 October 2024. Retrieved 3 January 2025.
"Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss". US Food and Drug Administration (FDA). 21 December 2023. Archived from the original on 29 December 2023. Retrieved 29 December 2023.
"Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity". US Food and Drug Administration (FDA). 11 January 2024. Archived from the original on 19 January 2024. Retrieved 19 January 2024.

accessdata.fda.gov

"Drug Approval Package: Ozempic (semaglutide) Injection". US Food and Drug Administration (FDA). 16 January 2018. Archived from the original on 1 March 2021. Retrieved 26 September 2020.
"Drug Approval Package: Rybelsus". US Food and Drug Administration (FDA). 10 June 2020. Archived from the original on 2 November 2020. Retrieved 26 September 2020.

dps.fda.gov

"Drug Shortages: Semaglutide Injection". U.S. Food and Drug Administration (FDA). Retrieved 3 January 2025.

funnelback.com

tga-search.clients.funnelback.com

"Summary for ARTG Entry:315107 Ozempic 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 6 June 2021.
"Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 23 February 2022.

globenewswire.com

"Novo Nordisk A/S: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes" (Press release). Novo Nordisk A/S. 9 February 2018. Archived from the original on 2 April 2019. Retrieved 19 August 2018 – via GlobeNewswire.
"Ozempic approved in Japan for the treatment of type 2 diabetes" (Press release). Novo Nordisk A/S. 23 March 2018. Archived from the original on 2 April 2019. Retrieved 2 April 2019 – via GlobeNewswire.

goodrx.com

Alyssa Billingsley (26 November 2024). "Is Semaglutide in Shortage? The Latest on Ozempic and Wegovy Availability". GoodRx.

gov.uk

"Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products". Medicines and Healthcare products Regulatory Agency. 23 November 2023. Archived from the original on 26 December 2023. Retrieved 6 January 2024.

handle.net

hdl.handle.net

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. (November 2016). "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 375 (19): 1834–1844. doi:10.1056/NEJMoa1607141. hdl:11268/7179. PMID 27633186.

hres.ca

pdf.hres.ca

Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (Report). Novo-Nordisk Canada. 21 August 2020 [Initial approval 4 January 2018]. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.
Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (Report). Novo-Nordisk Canada. 30 March 2020. Archived (PDF) from the original on 14 December 2021. Retrieved 6 June 2021.

hpr-rps.hres.ca

"Regulatory Decision Summary – Rybelsus". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
"Regulatory Decision Summary – Ozempic". Health Canada. 23 October 2014. Archived from the original on 17 May 2019. Retrieved 2 April 2019.

jpma.org.pk

Kalra S, Gupta Y (July 2015). "Once-weekly glucagon-like peptide 1 receptor agonists". The Journal of the Pakistan Medical Association. 65 (7): 796–8. PMID 26160096. Archived from the original on 30 September 2022. Retrieved 10 April 2022.

kff.org

"2024 Employer Health Benefits Survey". KFF. 9 October 2024. Retrieved 1 January 2025.

labiotech.eu

Adam J (16 June 2025). "Did Novo open the Canadian market to GLP-1 generics?".

lww.com

journals.lww.com

Mawardi HH, Almazrooa SA, Dakhil SA, Aboalola AA, Al-Ghalib TA, Eshky RT, et al. (29 December 2023). "Semaglutide-associated hyposalivation: A report of case series". Medicine. 102 (52): e36730.

medicaleconomics.com

"U.S. Leads the world in list prices for diabetes, antiobesity meds". 21 August 2023. Archived from the original on 20 January 2024. Retrieved 20 January 2024.

medicines.org.uk

"Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC)". (emc). 9 April 2021. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Rybelsus – Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen SmPC". (emc). 27 November 2024. Retrieved 26 December 2024.

medium.com

veronicamathews.medium.com

Mathews V (29 May 2025). "Fast Fix, Fading Faces: The Quiet Side Effects of America's Weight-Loss Craze". Medium. pp. Paragraph : A Conversation That Changed My View.

medrxiv.org

Sodhi M, Rezaeianzadeh R, Kezouh A, Frey C, Etminan M (6 March 2025). "Risk of Hair Loss with Semaglutide for Weight Loss". medRxiv 10.1101/2025.02.23.25322568.

nice.org.uk

"NICE recommended weight-loss drug to be made available in specialist NHS services". National Institute for Health and Care Excellence (NICE). 8 March 2023. Archived from the original on 9 March 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.
Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982.
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.
Goldenberg RM, Steen O (March 2019). "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes". Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966.
Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (November 2023). "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss". JAMA. 330 (18): 1795–1797. doi:10.1001/jama.2023.19574. PMC 10557026. PMID 37796527.
Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA (April 2020). "Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials". Diabetes, Obesity & Metabolism. 22 (4): 699–704. doi:10.1111/dom.13924. PMID 31750601.
Sande CM, Tondi Resta I, Livolsi VA (March 2023). "The Thyroid Pathologist Meets Therapeutic Pharmacology". Endocrine Pathology. 34 (1): 48–56. doi:10.1007/s12022-023-09749-1. PMC 9890439. PMID 36723855.
Shor R, Mihalache A, Noori A, Shor R, Kohly RP, Popovic MM, et al. (5 June 2025). "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration". JAMA Ophthalmology. doi:10.1001/jamaophthalmol.2025.1455. ISSN 2168-6165. PMC 12142475. PMID 40471562.
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. (April 2010). "Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation". Endocrinology. 151 (4): 1473–1486. doi:10.1210/en.2009-1272. PMID 20203154. S2CID 20934882.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. (November 2016). "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 375 (19): 1834–1844. doi:10.1056/NEJMoa1607141. hdl:11268/7179. PMID 27633186.
Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D (2003). "Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis". The Journal of Biological Chemistry. 278 (1): 471–478. doi:10.1074/jbc.M209423200. PMID 12409292.
Dhillon S (February 2018). "Semaglutide: First Global Approval". Drugs. 78 (2): 275–284. doi:10.1007/s40265-018-0871-0. PMID 29363040. S2CID 46851453.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. (September 2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (September 2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide". Journal of Medicinal Chemistry. 58 (18): 7370–80. doi:10.1021/acs.jmedchem.5b00726. PMID 26308095. S2CID 20228358.
Gotfredsen CF, Mølck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, et al. (July 2014). "The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates". Diabetes. 63 (7): 2486–97. doi:10.2337/db13-1087. PMID 24608440. S2CID 35102048.
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A (May 2015). "Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel". Journal of Clinical Pharmacology. 55 (5): 497–504. doi:10.1002/jcph.443. PMC 4418331. PMID 25475122.
Kalra S, Gupta Y (July 2015). "Once-weekly glucagon-like peptide 1 receptor agonists". The Journal of the Pakistan Medical Association. 65 (7): 796–8. PMID 26160096. Archived from the original on 30 September 2022. Retrieved 10 April 2022.
Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". The New England Journal of Medicine. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID 33567185. S2CID 231883214.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. (October 2022). "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial". Nature Medicine. 28 (10): 2083–2091. doi:10.1038/s41591-022-02026-4. PMC 9556320. PMID 36216945.
Müller TD, Blüher M, Tschöp MH, DiMarchi RD (March 2022). "Anti-obesity drug discovery: advances and challenges". Nature Reviews. Drug Discovery. 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. PMC 8609996. PMID 34815532.
Claxton G, Rae M, Damico A, Winger A, Wager E (November 2024). "Health Benefits In 2024: Higher Premiums Persist, Employer Strategies For GLP-1 Coverage And Family-Building Benefits". Health Affairs. 43 (11): 1491–1501. doi:10.1377/hlthaff.2024.01006. PMID 39381848.
Tichy EM, Hoffman JM, Tadrous M, Rim MH, Cuellar S, Clark JS, et al. (July 2024). "National trends in prescription drug expenditures and projections for 2024". American Journal of Health-System Pharmacy. 81 (14): 583–598. doi:10.1093/ajhp/zxae105. PMID 38656319.
Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M (June 2022). "Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis". Diabetes & Metabolic Syndrome. 16 (6): 102539. doi:10.1016/j.dsx.2022.102539. PMID 35709586. S2CID 249584781.
Nagendra L, Bg H, Sharma M, Dutta D (July 2023). "Semaglutide and cancer: A systematic review and meta-analysis.". Diabetes Metab Syndr. 17 (9): 102834. doi:10.1016/j.dsx.2023.102834. PMID 37531876. S2CID 260261877.
Wilding JP, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. (August 2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension". Diabetes, Obesity & Metabolism. 24 (8): 1553–1564. doi:10.1111/dom.14725. PMC 9542252. PMID 35441470.
Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (April 2024). "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials". Expert Opinion on Pharmacotherapy. 25 (5): 611–619. doi:10.1080/14656566.2024.2343092. PMID 38629387.
Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, et al. (April 2025). "A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies". Journal of Drugs in Dermatology. 24 (4): 413–415. doi:10.36849/JDD.8605. PMID 40196945.

ncbi.nlm.nih.gov

Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (November 2023). "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss". JAMA. 330 (18): 1795–1797. doi:10.1001/jama.2023.19574. PMC 10557026. PMID 37796527.
Sande CM, Tondi Resta I, Livolsi VA (March 2023). "The Thyroid Pathologist Meets Therapeutic Pharmacology". Endocrine Pathology. 34 (1): 48–56. doi:10.1007/s12022-023-09749-1. PMC 9890439. PMID 36723855.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. (September 2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A (May 2015). "Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel". Journal of Clinical Pharmacology. 55 (5): 497–504. doi:10.1002/jcph.443. PMC 4418331. PMID 25475122.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. (October 2022). "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial". Nature Medicine. 28 (10): 2083–2091. doi:10.1038/s41591-022-02026-4. PMC 9556320. PMID 36216945.
Müller TD, Blüher M, Tschöp MH, DiMarchi RD (March 2022). "Anti-obesity drug discovery: advances and challenges". Nature Reviews. Drug Discovery. 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. PMC 8609996. PMID 34815532.
Wilding JP, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. (August 2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension". Diabetes, Obesity & Metabolism. 24 (8): 1553–1564. doi:10.1111/dom.14725. PMC 9542252. PMID 35441470.

dailymed.nlm.nih.gov

"Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
"Rybelsus- oral semaglutide tablet". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
"Wegovy- semaglutide injection, solution". DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022.

novonordisk.com

"Ozempic (semaglutide) approved in the US" (Press release). Novo Nordisk. 5 December 2017. Archived from the original on 5 June 2021. Retrieved 5 June 2021.

npr.org

Lupkin S (30 May 2024). "Compounding pharmacies are making their own versions of blockbuster weight loss drugs". NPR. Retrieved 3 January 2025.
Lupkin S (7 June 2024). "Thinking of buying Wegovy online? Here's what to know about compounding pharmacies". NPR.

nytimes.com

Blum D (22 November 2022). "What Is Ozempic and Why Is It Getting So Much Attention?". The New York Times. ISSN 0362-4331. Archived from the original on 29 March 2023. Retrieved 30 March 2023.
Robbins R (26 January 2024). "Buried in Wegovy Costs, North Carolina Will Stop Paying for Obesity Drugs". The New York Times. Retrieved 26 December 2024.
Margot Sanger-Katz (30 August 2024). "The State That Chose to Cover Obesity Drugs for Its Poor, but Not Its Own Employees". The New York Times.
Margot Sanger-Katz (26 November 2024). "Obesity Drugs Would Be Covered by Medicare and Medicaid Under Biden Proposal". The New York Times.
Kolata G (28 April 2022). "Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims". The New York Times. Archived from the original on 27 June 2022. Retrieved 13 May 2022.
Nelson E (20 April 2024). "It Introduced Ozempic to the World. Now It Must Remake Itself". The New York Times. p. B1.

pbs.gov.au

"SEMAGLUTIDE". Pharmaceutical Benefits Scheme. Retrieved 2 June 2025.

people.com

Blanchet B (27 July 2023). "Ozempic, Drugs for Weight Loss Being Reviewed for Links to Suicide Risk". People. Archived from the original on 28 July 2023. Retrieved 28 July 2023.

pharmaceutical-technology.com

Masters W (9 May 2023). "Brazilian federal court denies semaglutide patent extension". Pharmaceutical Technology. Archived from the original on 6 January 2024. Retrieved 1 December 2023.

prnewswire.com

"Novo Nordisk announces FDA approval of label update for Rybelsus (semaglutide) allowing use as a first-line option for adults with type 2 diabetes" (Press release). Novo Nordisk. 12 January 2023. Archived from the original on 16 January 2023. Retrieved 16 January 2023 – via PR Newswire.

qut.edu.au

eprints.qut.edu.au

Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.

reuters.com

Fick M, Fick M (5 October 2023). "Novo Nordisk's Wegovy bonanza looms large in Denmark". Reuters. Retrieved 5 April 2024.
"European regulator warns EU, UK about fake Ozempic pens". Reuters. 18 October 2023. Archived from the original on 24 October 2023. Retrieved 24 October 2023.
"Novo Nordisk says stopping obesity drug may cause full weight regain in 5 years". Reuters. 30 March 2023. Archived from the original on 10 June 2023. Retrieved 12 February 2024.

semanticscholar.org

api.semanticscholar.org

Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.
Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982.
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. (April 2010). "Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation". Endocrinology. 151 (4): 1473–1486. doi:10.1210/en.2009-1272. PMID 20203154. S2CID 20934882.
Dhillon S (February 2018). "Semaglutide: First Global Approval". Drugs. 78 (2): 275–284. doi:10.1007/s40265-018-0871-0. PMID 29363040. S2CID 46851453.
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. (September 2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide". Journal of Medicinal Chemistry. 58 (18): 7370–80. doi:10.1021/acs.jmedchem.5b00726. PMID 26308095. S2CID 20228358.
Gotfredsen CF, Mølck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, et al. (July 2014). "The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates". Diabetes. 63 (7): 2486–97. doi:10.2337/db13-1087. PMID 24608440. S2CID 35102048.
Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. (March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". The New England Journal of Medicine. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID 33567185. S2CID 231883214.
Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M (June 2022). "Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis". Diabetes & Metabolic Syndrome. 16 (6): 102539. doi:10.1016/j.dsx.2022.102539. PMID 35709586. S2CID 249584781.
Nagendra L, Bg H, Sharma M, Dutta D (July 2023). "Semaglutide and cancer: A systematic review and meta-analysis.". Diabetes Metab Syndr. 17 (9): 102834. doi:10.1016/j.dsx.2023.102834. PMID 37531876. S2CID 260261877.

spiegel.de

Müller MU, Preker A (4 January 2024). "Interview with Weight Loss Drugs Inventor Lotte Bjerre Knudsen: "I'm Experimenting with Periodic Fasting"". Der Spiegel. ISSN 2195-1349. Archived from the original on 25 August 2024. Retrieved 15 May 2024.

statnews.com

Cooney E (5 June 2025). "GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds". STAT. Retrieved 7 June 2025.

tga.gov.au

"AusPAR: Semaglutide". Therapeutic Goods Administration (TGA). 2 December 2020. Archived from the original on 24 February 2022. Retrieved 23 February 2022.
"Rybelsus APMDS". Therapeutic Goods Administration (TGA). 22 February 2022. Retrieved 23 February 2022.
"Wegovy (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 14 April 2023. Retrieved 7 April 2023.

theglobeandmail.com

"Cheaper, generic versions of Ozempic could come to Canada as early as next year". 11 March 2025 – via www.theglobeandmail.com.

theguardian.com

"Several hospitalised in Austria after using suspected fake diabetes drug". The Guardian. Reuters. 24 October 2023. Archived from the original on 24 October 2023. Retrieved 24 October 2023.

washingtonpost.com

Gilbert D (12 June 2023). "Insurers clamping down on doctors who prescribe Ozempic for weight loss". The Washington Post.
Marcus R (6 June 2023). "I lost 40 pounds on Ozempic. But I'm left with even more questions". The Washington Post. Archived from the original on 7 June 2023.
Ovalle D, Gilbert D (11 January 2024). "FDA reports no link between weight-loss drugs and suicidal thoughts". The Washington Post. Archived from the original on 14 January 2024. Retrieved 19 January 2024.

web.archive.org

"AusPAR: Semaglutide". Therapeutic Goods Administration (TGA). 2 December 2020. Archived from the original on 24 February 2022. Retrieved 23 February 2022.
"Summary for ARTG Entry:315107 Ozempic 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 6 June 2021.
"Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 23 February 2022.
"Wegovy (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 14 April 2023. Retrieved 7 April 2023.
Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (Report). Novo-Nordisk Canada. 21 August 2020 [Initial approval 4 January 2018]. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.
Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (Report). Novo-Nordisk Canada. 30 March 2020. Archived (PDF) from the original on 14 December 2021. Retrieved 6 June 2021.
"Regulatory Decision Summary – Rybelsus". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Archived from the original on 17 April 2024. Retrieved 17 April 2024.
"Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC)". (emc). 9 April 2021. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Rybelsus – Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
"Rybelsus- oral semaglutide tablet". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
"Wegovy- semaglutide injection, solution". DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022.
"Ozempic EPAR". European Medicines Agency (EMA). 8 February 2018. Archived from the original on 25 October 2020. Retrieved 26 September 2020.
"Rybelsus EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 14 August 2020. Retrieved 26 September 2020.
"Wegovy EPAR". European Medicines Agency. 6 January 2022. Archived from the original on 2 July 2022. Retrieved 11 March 2022.
"Wegovy Product information". Union Register of medicinal products. Archived from the original on 30 October 2022. Retrieved 3 March 2023.
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.
"Drug Approval Package: Ozempic (semaglutide) Injection". US Food and Drug Administration (FDA). 16 January 2018. Archived from the original on 1 March 2021. Retrieved 26 September 2020.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014". US Food and Drug Administration (FDA) (Press release). 4 June 2021. Archived from the original on 4 June 2021. Retrieved 5 June 2021.
"FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight". US Food and Drug Administration (FDA) (Press release). 8 March 2024. Archived from the original on 12 March 2024. Retrieved 12 March 2024. This article incorporates text from this source, which is in the public domain.
"Ozempic Drug Trial Snapshot". US Food and Drug Administration (FDA). 5 December 2017. Archived from the original on 31 December 2023. Retrieved 31 December 2023. This article incorporates text from this source, which is in the public domain.
Reynolds M. "What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know". Wired. ISSN 1059-1028. Archived from the original on 15 May 2024. Retrieved 15 May 2024.
Müller MU, Preker A (4 January 2024). "Interview with Weight Loss Drugs Inventor Lotte Bjerre Knudsen: "I'm Experimenting with Periodic Fasting"". Der Spiegel. ISSN 2195-1349. Archived from the original on 25 August 2024. Retrieved 15 May 2024.
Kalra S, Gupta Y (July 2015). "Once-weekly glucagon-like peptide 1 receptor agonists". The Journal of the Pakistan Medical Association. 65 (7): 796–8. PMID 26160096. Archived from the original on 30 September 2022. Retrieved 10 April 2022.
"Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)". ClinicalTrials.gov. October 2019. Archived from the original on 31 July 2018. Retrieved 3 March 2023.
Blum D (22 November 2022). "What Is Ozempic and Why Is It Getting So Much Attention?". The New York Times. ISSN 0362-4331. Archived from the original on 29 March 2023. Retrieved 30 March 2023.
Dillinger K (29 March 2023). "WHO advisers to consider whether obesity medication should be added to Essential Medicines List". CNN. Archived from the original on 30 March 2023. Retrieved 30 March 2023.
"Development Status and FDA Approval Process for semaglutide". Drugs.com. 2017. Archived from the original on 24 October 2017. Retrieved 24 October 2017.
"Ozempic (semaglutide) approved in the US" (Press release). Novo Nordisk. 5 December 2017. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
"Regulatory Decision Summary – Ozempic". Health Canada. 23 October 2014. Archived from the original on 17 May 2019. Retrieved 2 April 2019.
"Novo Nordisk A/S: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes" (Press release). Novo Nordisk A/S. 9 February 2018. Archived from the original on 2 April 2019. Retrieved 19 August 2018 – via GlobeNewswire.
"Ozempic approved in Japan for the treatment of type 2 diabetes" (Press release). Novo Nordisk A/S. 23 March 2018. Archived from the original on 2 April 2019. Retrieved 2 April 2019 – via GlobeNewswire.
"Drug Approval Package: Rybelsus". US Food and Drug Administration (FDA). 10 June 2020. Archived from the original on 2 November 2020. Retrieved 26 September 2020.
"FDA approves first oral GLP-1 treatment for type 2 diabetes" (Press release). US Food and Drug Administration (FDA). 20 September 2019. Archived from the original on 23 September 2019. Retrieved 20 September 2019.
"Wegovy: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 13 November 2021. Retrieved 13 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Novo Nordisk announces FDA approval of label update for Rybelsus (semaglutide) allowing use as a first-line option for adults with type 2 diabetes" (Press release). Novo Nordisk. 12 January 2023. Archived from the original on 16 January 2023. Retrieved 16 January 2023 – via PR Newswire.
"OZEMPIC Drug Patent Profile". Drug Patent Watch. Archived from the original on 23 March 2024. Retrieved 23 March 2024.
He L (7 June 2023). "Ozempic is taking China by storm. Drugmakers are scrambling to boost supplies". CNN Business. Archived from the original on 15 December 2023. Retrieved 1 December 2023.
Masters W (9 May 2023). "Brazilian federal court denies semaglutide patent extension". Pharmaceutical Technology. Archived from the original on 6 January 2024. Retrieved 1 December 2023.
"U.S. Leads the world in list prices for diabetes, antiobesity meds". 21 August 2023. Archived from the original on 20 January 2024. Retrieved 20 January 2024.
"Charted: The cost of weight-loss drugs in the US vs. Other countries". Archived from the original on 20 January 2024. Retrieved 8 April 2024.
Kolata G (28 April 2022). "Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims". The New York Times. Archived from the original on 27 June 2022. Retrieved 13 May 2022.
"NICE recommended weight-loss drug to be made available in specialist NHS services". National Institute for Health and Care Excellence (NICE). 8 March 2023. Archived from the original on 9 March 2023.
Marcus R (6 June 2023). "I lost 40 pounds on Ozempic. But I'm left with even more questions". The Washington Post. Archived from the original on 7 June 2023.
Verrender I (19 December 2023). "How Ozempic could affect the health of the global economy in more ways than one". ABC News. Archived from the original on 18 December 2023. Retrieved 18 December 2023.
"EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens". European Medicines Agency (Press release). 18 October 2023. Archived from the original on 4 January 2024. Retrieved 6 January 2024.
"Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products". Medicines and Healthcare products Regulatory Agency. 23 November 2023. Archived from the original on 26 December 2023. Retrieved 6 January 2024.
"European regulator warns EU, UK about fake Ozempic pens". Reuters. 18 October 2023. Archived from the original on 24 October 2023. Retrieved 24 October 2023.
"Several hospitalised in Austria after using suspected fake diabetes drug". The Guardian. Reuters. 24 October 2023. Archived from the original on 24 October 2023. Retrieved 24 October 2023.
"FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain". US Food and Drug Administration (FDA). 21 December 2023. Archived from the original on 22 December 2023. Retrieved 22 December 2023.
"Compounding when Drugs are on FDA's Drug Shortages List". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 28 September 2024. Retrieved 3 January 2025. This article incorporates text from this source, which is in the public domain.
"FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 3 October 2024. Retrieved 3 January 2025.
"Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss". US Food and Drug Administration (FDA). 21 December 2023. Archived from the original on 29 December 2023. Retrieved 29 December 2023.
"Novo Nordisk says stopping obesity drug may cause full weight regain in 5 years". Reuters. 30 March 2023. Archived from the original on 10 June 2023. Retrieved 12 February 2024.
Blanchet B (27 July 2023). "Ozempic, Drugs for Weight Loss Being Reviewed for Links to Suicide Risk". People. Archived from the original on 28 July 2023. Retrieved 28 July 2023.
"Weight-loss jabs investigated for suicide risk". BBC News. 10 July 2023. Archived from the original on 10 July 2023. Retrieved 10 July 2023.
Ovalle D, Gilbert D (11 January 2024). "FDA reports no link between weight-loss drugs and suicidal thoughts". The Washington Post. Archived from the original on 14 January 2024. Retrieved 19 January 2024.
"Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity". US Food and Drug Administration (FDA). 11 January 2024. Archived from the original on 19 January 2024. Retrieved 19 January 2024.

wired.com

Reynolds M. "What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know". Wired. ISSN 1059-1028. Archived from the original on 15 May 2024. Retrieved 15 May 2024.

worldcat.org

search.worldcat.org

Shor R, Mihalache A, Noori A, Shor R, Kohly RP, Popovic MM, et al. (5 June 2025). "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration". JAMA Ophthalmology. doi:10.1001/jamaophthalmol.2025.1455. ISSN 2168-6165. PMC 12142475. PMID 40471562.
Reynolds M. "What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know". Wired. ISSN 1059-1028. Archived from the original on 15 May 2024. Retrieved 15 May 2024.
Müller MU, Preker A (4 January 2024). "Interview with Weight Loss Drugs Inventor Lotte Bjerre Knudsen: "I'm Experimenting with Periodic Fasting"". Der Spiegel. ISSN 2195-1349. Archived from the original on 25 August 2024. Retrieved 15 May 2024.
Blum D (22 November 2022). "What Is Ozempic and Why Is It Getting So Much Attention?". The New York Times. ISSN 0362-4331. Archived from the original on 29 March 2023. Retrieved 30 March 2023.

yle.fi

"Finns' appetite for weightloss drugs grows". YLE. Retrieved 14 June 2025.